Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 9/20 | 0.50 |
| ▸ | MEN1 | O00255 | 8/20 | 0.50 |
| ▸ | CA1 | P00915 | 7/20 | 0.48 |
| ▸ | CA2 | P00918 | 7/20 | 0.48 |
| ▸ | ESR1 | P03372 | 5/20 | 0.48 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.48 |
| ▸ | ATM | Q13315 | 1/20 | 0.48 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.37 |
| ▸ | SENP8 | Q96LD8 | 2/20 | 0.37 |
| ▸ | SENP7 | Q9BQF6 | 2/20 | 0.37 |
| ▸ | SENP6 | Q9GZR1 | 2/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | CA9 | Q16790 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31299567 | 0.85 | CA1 (0.53) | KMT2AMEN1CA1CA2ESR1 | |
| SCHEMBL2226088 | 0.84 | CA1 (0.49) | KMT2AMEN1CA1CA2CA9 | |
| SCHEMBL31440230 | 0.84 | CA1 (0.53) | KMT2AMEN1CA1CA2ESR1 | |
| SCHEMBL1897441 | 0.83 | KMT2A (0.56) | KMT2AMEN1CA1CA2ESR1 | |
| SCHEMBL13953557 | 0.80 | KMT2A (0.52) | KMT2AMEN1CA1CA2ESR1 | |
| SCHEMBL15205101 | 0.80 | MEN1 (0.51) | KMT2AMEN1CA1CA2ESR1 | |
| SCHEMBL575913 | 0.78 | CA2 (0.51) | CA1CA2CA9 | |
| SCHEMBL9144711 | 0.76 | CYP1A2 (0.41) | KMT2AMEN1ESR1ESR2ATM | |
| SCHEMBL21811659 | 0.76 | CA1 (0.42) | KMT2AMEN1CA1CA2ESR1 | |
| SCHEMBL12673293 | 0.75 | KMT2A (0.48) | KMT2AMEN1CA1CA2ESR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120283216-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY | 2012-11-08 | — | — | US | disclosed |
| EP-2516385-A2 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. du Pont de Nemours and Company (US) | 2012-10-31 | — | — | EP | disclosed |
| WO-2012087372-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2012-06-28 | — | — | WO | disclosed |
| WO-2011087837-A9 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-09-09 | — | — | WO | disclosed |
| WO-2011087837-A2 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | E. I. DU PONT DE NEMOURS AND COMPANY (US) | 2011-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120283216-A1 | FUNGICIDAL 2-(BICYCLIC ARYLOXY)CARBOXAMIDES | CBR3, CBR1, Q6ZSR9 | KMT2A 1406/4885MEN1 3096/4885CA1 1469/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.